Full-Time

Senior Analytical Scientist

Updated on 8/1/2026

Altasciences

Altasciences

1,001-5,000 employees

Integrated CRO for early-phase drug development

No salary listed

Harleysville, PA, USA

In Person

Bachelor's, Master's, PhD

Category
Lab & Research (1)
Required Skills
Data Visualization
GMP
Word/Pages/Docs
Excel/Numbers/Sheets
Microsoft Outlook

Get referred to Altasciences

See people who can refer or advise you

Requirements
  • A bachelor's degree in Engineering, Chemistry, Pharmaceutical Sciences, or a related field is required.
  • At least 8 years of current industry experience in analytical method development and qualification with a bachelor's degree, 5 years with a master's degree, or 3 years with a PhD is required.
  • Experience in modern dissolution method development and in vitro-in vivo correlation is required.
  • Experience applying current International Council for Harmonisation, United States Pharmacopeia, British Pharmacopoeia, European Pharmacopoeia, and Japanese Pharmacopoeia guidance to regulatory submissions is required.
  • Proficiency with Microsoft Word, Excel, Outlook, and scientific software is required.
  • Extensive hands-on experience with quantitative tests including assay, content uniformity, dissolution, particle size distribution, preservative assay, related substances, residual solvents, resuspendability, and viscosity for oral solid dosage forms is required.
  • Experience with high-performance liquid chromatography, ultra-performance liquid chromatography, disintegration testing, ultraviolet testing, Karl Fischer testing, titrations, and other compendial or generic testing is required.
  • Proficiency in analytical instrumentation and troubleshooting is required.
  • Experience in a regulated laboratory environment using good laboratory practice and good manufacturing practice is required.
  • Experience mentoring team members is required.
  • Experience with laboratory current good manufacturing practice regulations from the Food and Drug Administration and European Medicines Agency, and with pharmaceutical quality systems, is required.
  • Ability to manage multiple projects in a fast-paced setting is required.
  • Ability to identify and anticipate client needs and make implementation recommendations is required.
  • Strong presentation, communication, interpersonal, and facilitation abilities are required.
Responsibilities
  • Design and manage analytical approaches supporting early drug development projects, including research and development, preclinical, and Phase I clinical projects, with emphasis on chromatographic, dissolution, particle size distribution, and spectrophotometry-based methods.
  • Oversee and review the planning, development, execution, and interpretation of analytical studies performed by other scientists.
  • Lead the development, qualification, validation, and transfer of robust analytical methods to ensure high-quality, reproducible data.
  • Collaborate cross-functionally to identify and apply analytical techniques, including computational modeling, predictive tools, and data visualization platforms.
  • Ensure analytical methods follow International Council for Harmonisation Q2 and Q14 principles.
  • Lead the planning, execution, and interpretation of analytical method studies.
  • Evaluate scientific data, draw conclusions, guide future work, and communicate findings through presentations, technical reports, and other media.
  • Author relevant quality-module sections for regulatory submissions in alignment with global standards.
  • Work with formulation development, manufacturing, and quality teams to select and apply analytical techniques.
  • Lead analytical method development projects from start to finish and mentor junior scientists.
  • Develop and implement new analytical technologies and high-throughput workflows.
Desired Qualifications
  • A master's or PhD degree in Engineering, Chemistry, Pharmaceutical Sciences, or a related field is preferred.
  • Experience with multiple dosage forms, such as solid oral, peptides, sterile, biologics, or specialized manufacturing.

Altasciences provides an integrated CRO that handles the full early‑phase drug development path, from preclinical testing through clinical proof of concept and into manufacturing. Its approach combines discovery support, safety testing, clinical trial execution, and in‑house manufacturing to run programs under one roof. This contrasts with competitors that require pharma and biotech clients to source services from multiple vendors, adding complexity and risk; Altasciences streamlines the process by coordinating all steps. The company aims to help innovator drug programs move quickly and efficiently, delivering integrated data to de‑risk decisions and speed progression to later stages.

Company Size

1,001-5,000

Company Stage

Early VC

Total Funding

$6.7M

Headquarters

Laval, Canada

Founded

1976

Get referred to Altasciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 30, 2026 Steel Therapeutics study advanced Fizurex toward an IND submission.
  • August 4, 2026 Harleysville expanded R&D labs, tightening formulation and analytics loops.
  • February 24, 2026 CEO Marie-Hélène Raigneau unified leadership after Chris Perkin's board move.

What critics are saying

  • Everett's 2024 USDA animal-welfare fine still shadows primate work and sponsor diligence.
  • A serious recurrence at Everett triggers sponsor exits and fresh USDA restrictions.
  • Heavy integration raises execution risk if AI, labs, or manufacturing underdeliver together.

What makes Altasciences unique

  • Altasciences spans preclinical, clinical, bioanalytical, and CDMO services across eight North American sites.
  • Certara partnership on May 7, 2026 embeds MIDD into execution workflows.
  • Evidence Matters and VoxCell collaborations push AI writing and human-relevant preclinical models.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Employee Assistance & Telehealth Programs

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

4%

2 year growth

8%
Associated Press
Jul 7th, 2026
Altasciences and Evidence Matters extend AI automation from clinical to nonclinical drug development

Altasciences and Evidence Matters have completed a successful proof-of-concept for RegulatoryFlow, an AI platform extending automation from clinical to nonclinical drug development workflows. The collaboration, announced in August 2025, demonstrated accurate parsing of raw and SEND datasets, potentially expediting nonclinical reporting timelines. The current RegFlow version can generate approximately one-third of a typical nonclinical report with high fidelity. The platform has already achieved production of first-draft clinical study reports in clinical workflows. Marie-Hélène Raigneau, CEO of Altasciences, said the milestone helps sponsors move from initial safety assessments to clinical proof-of-concept faster whilst maintaining scientific integrity. Dr Ofer Avital, founder of Evidence Matters, noted the technology creates an AI bridge between nonclinical and clinical phases, freeing resources for higher-value scientific work.

Certara
May 7th, 2026
Altasciences and Certara announce strategic partnership to accelerate early drug development.

Altasciences and Certara announce strategic partnership to accelerate early drug development. LAVAL, Québec, and Radnor, PA - May 7, 2026 - Altasciences, a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences' Acceleration Platform, the integration of Certara's strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies are refined, and programs are more seamlessly integrated across nonclinical, clinical, bioanalytical, and manufacturing services. "At Altasciences, we already help sponsors move from first safety assessment to proof of concept with speed and precision," said Marie-Hélène Raigneau, CEO of Altasciences. "By embedding Certara's modeling capabilities into our platform, we can further inform critical decisions earlier and with greater confidence. This collaboration is about reducing uncertainty at the moments that matter most." The partnership comes at an opportune time as the FDA continues to advance new guidance supporting more adaptive, data-driven, and real-time drug development approaches, capabilities that integrated MIDD execution models are well positioned to deliver. "This partnership unlocks new opportunities to improve early development decisions for biotech sponsors and their investors," said Jon Resnick, CEO of Certara. "By embedding modeling and simulation directly into execution, we enable faster, more informed decision-making that ultimately benefits patients." Together, Altasciences and Certara are advancing a model-first, fully integrated, and resource-efficient approach to early drug development that accelerates the path to proof of concept for biotech innovators, investors and pharmaceutical companies across the globe. About Altasciences. Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical study programs, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences' integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. About Certara. Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Visit Certara Inc. at www.certara.com. Certara contact: Media contact:

GlobeNewswire
Mar 16th, 2026
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard...

Business Wire
Aug 20th, 2025
Altasciences Receives EcoVadis Gold Medal for Environmental, Social, and Governance (ESG) Efforts

EcoVadis, the world's most trusted provider of business sustainability ratings, has collaborated closely with Altasciences to enhance its environmental, social, and governance (ESG) initiatives, underscoring the company's commitment to a sustainable future and a reduced environmental footprint.

Yahoo Finance
Jul 31st, 2025
Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development

This partnership combines Altasciences' comprehensive early-phase drug development capabilities with VoxCell's cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment.